The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus

International Journal of Infectious Diseases

Volumn 17, Issue 8, 2013, Pages

  Huang, Li Hua ^a   Qiu, Yuan Wang ^a   Hua, Hai Yong ^b   Niu, Xue Hua ^c   Wu, Peng Fei ^c   Wu, Hang Yuan ^a   Zhu, Hong Ying ^a   Yang, Xiao Juan ^a   Yao, Shang Zhi ^a   Li, Yi Guang ^a  

^a WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Institute of Parasite Diseases   (China)

^c The Third People's Hospital of Kunshan   (China)

Author keywords

Advanced schistosomiasis japonica; Efficacy; Entecavir; Hepatitis B virus

Indexed keywords

ALANINE AMINOTRANSFERASE; COLLAGEN TYPE 4; ENTECAVIR; FIBRONECTIN; HYALURONIC ACID; LAMININ; PROCOLLAGEN; PROCOLLAGEN TYPE 3; UNCLASSIFIED DRUG; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHILD PUGH SCORE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; ISHAK FIBROSIS SCORE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCHISTOSOMIASIS; SCHISTOSOMIASIS JAPONICA; SCORING SYSTEM; WORM EXPULSION;

EID: 84891372739     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.01.023     Document Type: Article

References (30)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006;368:1106-18.
2. Wang L, Utzinge J, Zhou XN. Schistosomiasis control: experiences and lessons from China. Lancet 2008;372:1793-5.
3. Matsuda M, Fujii H. Chronic schistosomiasis japonica is an independent adverse prognostic factor for survival in hepatocellular carcinoma patients who have undergone hepatic resection: clinicopathological and prognostic analysis of 198 consecutive patients. World J Surg 2009;33:2644-50.
4. Jia TW, Utzinger J, Deng Y, Yang K, Li YY, Zhu JH, et al. Quantifying quality of life and disability of patients with advanced schistosomiasis japonica. PLoS Negl Trop Dis 2011;5:e966.
5. Ma C, Brunt EM. Histopathologic evaluation of liver biopsy for cirrhosis. Adv Anat Pathol 2012;19:220-30.
6. El-Sayed HF, Abaza SM, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop 1997;68:229-37.
7. Silva JL, de Souza VS, Vilella TA, Domingues AL, Coêlho MR. HBV and HCV serological markers in patients with the hepatosplenic form of mansonic schistosomiasis. Arq Gastroenterol 2011;48:124-30.
8. McManus DP, Gray DJ, Ross AG, Williams GM, He HB, Li YS. Schistosomiasis research in the Dongting Lake region and its impact on local and national treatment and control in China. PLoS Negl Trop Dis 2011;5:e1053.
9. McManus DP, Gray D, Li YS, Zheng F, Williams G, Stewartet D, et al. Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam. Clin Microbiol Rev 2010;23:442-66.
10. Zhou XN, Bergquist R, Leonardo L, Yang GJ, Yang K, Sudomo M, et al. Schistosomiasis japonica control and research needs. Adv Parasitol 2010;72:145-78.
11. Wang LD, Chen HG, Guo JG, Zeng XJ, Hong XL, Jiong JJ, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009;360:121-8.
12. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. ETV versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
13. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of ETV in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82.
14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
16. Jia ZH, Chu DY, Wang W, Luo QL, Shen JL. Effects of HBV infection on hepatic fibrosis and level of Th1/Th2 cytokines in the patients with Schistosomiasis japonica. Zhonghua Jian Yan Yi Xue Za Zhi 2007;30:1105-8.
17. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011;19:13-24.
18. Lu FM, Zhuang H. Management of hepatitis B in China. Chinese Medical Journal 2009;122:3-4.
19. Zhang JF, Wen LY, Zhu MD, Yan XL, Chen W, Li L, et al. Recent investigation and treatment of 1060 advanced schistosomiasis japonica cases in Zhejiang Province. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing 2010;28:214-7.
20. Zhang S, Li Z, Cai S, Zeng L. Observation of T lymphocyte subsets in the liver of patients with advanced schistosomiasis and advanced schistosomiasis accompanied with hepatitis B. J Tongji Med Univ 2000;20:137-8.
21. Zhang WC, Mao YF. Re-understanding of liver cirrhosis induced by Schistosomiasis japonica. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing 2006;24:382-4.
22. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
23. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61.
24. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
25. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of ETV in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82.
26. Chang TT, Liaw YF, Wu SS, SchiffE, Han KH, Lai CL, et al. Long-term ETV therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
27. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, et al. Long-term monitoring shows hepatitis B virus resistance to ETV in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
28. Cai WM, Tao J, Weng HL, Liu RH. Study on the influence factors of the serum fibrosis markers. Zhonghua Gan Zang Bing Za Zhi 2003;11:23-5.
29. Tao J, Peng HQ, Cai WM, Dong FQ, Weng HL, Liu RH. Influence factors of serum fibrosis markers in liver fibrosis. World J Gastroenterol 2003;9:2497-500.
30. SchiffER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al. Long-term treatment with ETV induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274-6.